Journal
EXPERT REVIEW OF CARDIOVASCULAR THERAPY
Volume 8, Issue 7, Pages 1015-1029Publisher
TAYLOR & FRANCIS INC
DOI: 10.1586/ERC.10.45
Keywords
ApoB48; atherosclerosis; diabetes; intestinal lipoproteins; lipoproteins; postprandial; triglycerides
Categories
Funding
- MSD
- Johnson and Johnson
- Eli Lilly
- Surface Logix Inc
- Takeda
- Merck
- Lypha
- Fournier
Ask authors/readers for more resources
The enormous burden of vascular disease is likely to expand rapidly as sedentary obesity and diabetes increase. Although cholesterol plays a major role in atherosclerosis and LDL is the major carrier of cholesterol in the blood, the importance of the postprandial triglyceride-rich lipoproteins in the development of atherosclerosis is gaining recognition. The role of HDL-cholesterol is also receiving more attention. These changes have been forced upon us by the realization that statins, which primarily lower LDL-cholesterol, only reduce the risk of atherosclerosis by 30%, suggesting that 70% of the risk still has to be explained and treated. In diabetes, abnormality in the metabolism of the triglyceride-rich lipoproteins and the inter-relationship with HDL-cholesterol appears to be of primary importance in atherosclerotic risk. Postprandial studies are difficult to carry out, which is one reason why large studies have not so far been performed. The important new findings in chylomicron metabolism suggest new treatments for the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available